Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $82.7M | $194M | $265M | $307M | $381M | $539M | $699M | $938M | $807M | $1.73B |
| Revenue growth | — | 135.0% | 36.2% | 16.0% | 24.0% | 41.4% | 29.7% | 34.2% | -14.0% | 114.5% |
| Operating income | -$132M | -$64.3M | -$116M | -$241M | -$432M | -$374M | -$447M | -$440M | -$303M | $867M |
| Operating margin | -159.7% | -33.1% | -43.7% | -78.6% | -113.4% | -69.5% | -64.0% | -46.9% | -37.5% | 50.1% |
| Net income | -$142M | -$79.0M | -$128M | -$252M | -$438M | -$524M | -$559M | -$627M | -$363M | $683M |
| Net margin | -171.8% | -40.6% | -48.4% | -82.0% | -115.1% | -97.3% | -80.0% | -66.8% | -45.0% | 39.4% |
| EPS (diluted) | -$4.17 | -$2.02 | -$2.75 | -$4.27 | -$6.64 | -$7.43 | -$7.79 | -$8.37 | -$4.73 | $7.78 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$104M | -$10.1M | -$27.6M | -$98.6M | -$194M | -$251M | -$357M | -$158M | -$108M | $711M |
| Capital expenditures | $1.78M | $3.10M | $7.10M | $13.8M | $17.8M | $28.2M | $32.0M | $28.4M | $6.50M | $8.86M |
| Free cash flow | -$105M | -$13.2M | -$34.7M | -$112M | -$212M | -$280M | -$389M | -$187M | -$114M | $702M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $58.3M | $112M | $169M | $288M | $209M | $190M | $280M | $594M | $780M | $985M |
| Total assets | $269M | $392M | $1.12B | $1.62B | $2.21B | $1.94B | $1.71B | $1.90B | $1.71B | $2.90B |
| Total liabilities | $150M | $235M | $768M | $1.03B | $1.73B | $1.94B | $2.05B | $2.71B | $2.80B | $3.10B |
| Long-term debt | $98.2M | $145M | $141M | $294M | $309M | $282M | $572M | $284M | $285M | — |
| Shareholders' equity | $120M | $156M | $351M | $594M | $482M | $1.44M | -$347M | -$819M | -$1.10B | -$205M |
| Retained earnings | -$735M | -$814M | -$939M | -$1.19B | -$1.63B | -$2.10B | -$2.66B | -$3.28B | -$3.65B | -$2.96B |
| Shares (wtd avg diluted) | 34.2M | 41.6M | 50.6M | 58.9M | 66.0M | 70.5M | 71.7M | 74.8M | 76.8M | 88.3M |
Every figure is extracted from PTC THERAPEUTICS, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.